Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2/3 1

Status

Active not recruiting 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Stage I Prostate Adenocarcinoma AJCC v7 1Prostatic Neoplasms 1Prostate Adenocarcinoma 1

Interventions

Magnetic Resonance Spectroscopy 107Specimen Handling 89pembrolizumab 82enzalutamide 65Nivolumab 64Gemcitabine 59Docetaxel 51Abiraterone Acetate 44apalutamide 43Radiosurgery 43Androgen Antagonists 43Prednisone 42darolutamide 40Cisplatin 38Biopsy 38cabozantinib 34Radiotherapy 34Carboplatin 30abiraterone 29Pluvicto 29Ipilimumab 29durvalumab 25enfortumab vedotin 24Leuprolide 24X-Rays 23Radiation 23atezolizumab 22olaparib 20Standard of Care 20avelumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Salicylic Acid × Genitourinary × 90 days × Clear all
NCT03070886 2026-05-07

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

NRG Oncology

Phase 2/3 Completed
612 enrolled
Genitourinary

Stage I Prostate Adenocarcinoma AJCC v7

NCT04513717 2026-05-04

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

NRG Oncology

Phase 3 Active not recruiting
2,753 enrolled
Genitourinary

Prostatic Neoplasms

NCT05050084 2026-05-04

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

NRG Oncology

Phase 3 Active not recruiting
2,050 enrolled
Genitourinary

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡